Archives
-
OTUD3, SLC7A11, and Sunitinib Resistance in ccRCC
2026-10-08
A 2025 Cancer Letters study identifies OTUD3-mediated stabilization of SLC7A11 as a mechanism that protects clear cell renal cell carcinoma from sunitinib-induced ferroptosis. The findings connect deubiquitination, cystine metabolism, redox control, and treatment resistance, while also defining important boundaries between ferroptosis-focused research and apoptosis inhibition.
-
Sodium Ascorbate in Oncology: Evidence and Limits
2026-10-08
Sodium Ascorbate is a mineral salt of ascorbic acid studied in redox biology and cancer models. Available supplier material describes promising glioblastoma and prostate cancer findings, but the supplied evidence is not sufficient to establish clinical efficacy or a validated link to GPNMB-guided immunotherapy.
-
gamma-Glu-Cys Product Overview
2026-10-07
APExBIO identifies gamma-Glu-Cys (γ-Glu-Cys; SKU B7887) as a research-use biochemical intermediate associated with glutathione metabolism. No matched paper evidence was supplied, so performance and biological-use claims remain unverified.
-
PPP1R3G–PP1γ Control of RIPK1 Cell Death
2026-10-07
Du and colleagues identify PPP1R3G as a regulatory subunit that recruits PP1γ to RIPK1-containing complex I, removing inhibitory phosphorylation and enabling RIPK1 kinase activation. The study connects this phosphatase-dependent mechanism to RIPK1-dependent apoptosis, type I necroptosis, and protection from TNF-induced systemic inflammation in knockout mice.
-
Z-VAD-FMK in Apoptosis and ROS Cancer Research
2026-10-06
A source-grounded overview of Z-VAD-FMK as a caspase-pathway research tool, its conceptual relevance to ROS-driven cancer-cell death, and the limitations of interpreting apoptosis inhibition in studies of carrier-platin.
-
PERK Loss, SLC7A11, and Ferroptosis in Colorectal Cancer
2026-10-06
The 2023 Redox Biology study identifies PERK as a negative regulator of ferroptosis in colorectal cancer by linking PERK–ATF4 signaling to transcriptional maintenance of SLC7A11. Its cell, tumor, transcriptomic, and patient-sample evidence suggests that weakening this adaptive endoplasmic-reticulum stress response can increase lipid peroxidation and constrain tumor growth, while also defining important limits for translation beyond the studied models.
-
Z-LEHD-FMK: Irreversible Caspase-9 Inhibitor
2026-10-05
Z-LEHD-FMK is described as an irreversible caspase-9 inhibitor for probing mitochondria-mediated apoptosis. Evidence from a graphene-treated melanoma-cell study supports caspase-9 involvement in the observed apoptotic phenotype, while product-level neuroprotection and cytoprotection claims require model-specific validation.
-
BglII Restriction Endonuclease Overview
2026-10-05
BglII restriction endonuclease (SKU K3010) is a supplier-described DNA-cleaving enzyme that recognizes 5′-AGATCT-3′ and generates sticky ends. No matched paper or independent performance evidence was provided.
-
ATRX Loss and RTK Inhibitor Sensitivity in Glioma
2026-10-04
A 2022 study linked ATRX deficiency in high-grade glioma cells with increased sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors. Its main translational implication is that ATRX status may help contextualize responses in inhibitor studies and may warrant evaluation alongside temozolomide-based treatment strategies.
-
GA2, Caspase-11, and Macrophage Pyroptosis
2026-10-03
A 2025 study identifies ganglioside GA2 as a potential upstream trigger of caspase-4/11-dependent macrophage pyroptosis after arterial injury. Its findings connect lipid accumulation, inflammatory cell death, and intimal hyperplasia while highlighting a mechanistic pathway that still requires validation across human disease settings.
-
Erythrocyte Lysis in Translational Bone Research
2026-10-01
A mechanistic and strategic guide to using selective erythrocyte removal to improve blood-derived assays in translational bone and immunology research, with practical guidance for flow cytometry, nucleic acid extraction, and protein workflows.
-
Z-VAD-FMK for Apoptosis and Ferroptosis Studies
2026-10-01
Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor for separating caspase-dependent apoptosis from alternative cell-death programs. This guide translates its mechanism into practical workflows for THP-1, Jurkat T-cell, and cancer-cell assays, with special emphasis on ferroptosis research inspired by the NeuroD1-GPX4 study.
-
Z-VAD-FMK in Apoptosis Research Workflows
2026-09-30
Z-VAD-FMK provides a practical, cell-permeable way to test whether a phenotype depends on caspase-driven apoptosis rather than another regulated cell-death program. This guide connects inhibitor dosing, caspase activity measurement, immune-cell workflows, and ferroptosis-focused cancer research to improve experimental interpretation.
-
A40926 Workflow for Cell-Wall Antibiotic Research
2026-09-30
A40926 is a dalbavancin precursor that links mechanistic cell-wall studies with practical antibacterial screening, resistant-pathogen profiling, and glycopeptide pathway engineering. This workflow shows how to select assay conditions, interpret MIC results, and troubleshoot experimental variability across Gram-positive and Neisseria models.
-
Z-VAD-FMK: Mechanism and Apoptosis Research
2026-09-29
Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor used to test whether apoptosis contributes to a cellular phenotype. Evidence from NSCLC models shows that z vad fmk can restore viability after statin–erlotinib co-treatment, while product information supports applications in apoptosis inhibition, immune-cell regulation, and pathway analysis.